MY140903A - Imidazole derivatives used as tafia inhibitors - Google Patents

Imidazole derivatives used as tafia inhibitors

Info

Publication number
MY140903A
MY140903A MYPI20051748A MYPI20051748A MY140903A MY 140903 A MY140903 A MY 140903A MY PI20051748 A MYPI20051748 A MY PI20051748A MY PI20051748 A MYPI20051748 A MY PI20051748A MY 140903 A MY140903 A MY 140903A
Authority
MY
Malaysia
Prior art keywords
imidazole derivatives
derivatives used
tafia inhibitors
inhibitors
compounds
Prior art date
Application number
MYPI20051748A
Other languages
English (en)
Inventor
Christopher Dr Kallus
Holger Dr Heitsch
Andreas Dr Lindenschmidt
Sven Dr Grueneberg
Szillat Hauke
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34964308&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY140903(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of MY140903A publication Critical patent/MY140903A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MYPI20051748A 2004-04-22 2005-04-20 Imidazole derivatives used as tafia inhibitors MY140903A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004020186A DE102004020186A1 (de) 2004-04-22 2004-04-22 Heterocyclylessigsäuren als Inhibitoren von TAFla

Publications (1)

Publication Number Publication Date
MY140903A true MY140903A (en) 2010-01-29

Family

ID=34964308

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20051748A MY140903A (en) 2004-04-22 2005-04-20 Imidazole derivatives used as tafia inhibitors

Country Status (34)

Country Link
EP (2) EP1864979B1 (https=)
JP (1) JP4939401B2 (https=)
KR (1) KR101162047B1 (https=)
CN (1) CN100572376C (https=)
AR (1) AR053302A1 (https=)
AT (2) ATE386737T1 (https=)
AU (1) AU2005238144B2 (https=)
BR (1) BRPI0510159A (https=)
CA (1) CA2563401C (https=)
CR (1) CR8650A (https=)
CY (1) CY1108087T1 (https=)
DE (2) DE102004020186A1 (https=)
DK (1) DK1740569T3 (https=)
EC (1) ECSP066941A (https=)
ES (1) ES2299026T3 (https=)
HR (1) HRP20080099T3 (https=)
IL (1) IL178672A (https=)
MA (1) MA28543B1 (https=)
MY (1) MY140903A (https=)
NI (1) NI200600217A (https=)
NO (1) NO20065320L (https=)
NZ (1) NZ550757A (https=)
PE (1) PE20060172A1 (https=)
PL (1) PL1740569T3 (https=)
PT (1) PT1740569E (https=)
RS (1) RS50553B (https=)
RU (1) RU2375356C2 (https=)
SI (1) SI1740569T1 (https=)
TN (1) TNSN06341A1 (https=)
TW (1) TWI359016B (https=)
UA (1) UA87306C2 (https=)
UY (1) UY28868A1 (https=)
WO (1) WO2005105781A1 (https=)
ZA (1) ZA200607668B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20150514T1 (hr) 2006-12-06 2015-09-11 Sanofi DERIVATI SULFAMIDA KAO INHIBITORI TAFIa
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
MX2009008777A (es) * 2007-02-13 2009-08-25 Schering Corp Derivados y analogos de cromano como agonistas de los receptores alfa2c adrenergicos funcionalmente selectivos.
AU2008279447A1 (en) * 2007-07-19 2009-01-29 Metabolex, Inc. N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders
WO2009103432A2 (en) * 2008-02-21 2009-08-27 Sanofi-Aventis Covalently binding imaging probes
SI2300462T1 (sl) 2008-06-06 2014-09-30 Sanofi Makrociklični sečninski in sulfamidni derivati kot inhibitorji za TAFIa
NZ592764A (en) 2008-10-29 2012-08-31 Taisho Pharmaceutical Co Ltd Compound having tafia inhibitory activity
KR20120016651A (ko) * 2009-05-15 2012-02-24 사노피 Ｔａｆｉａ의 억제제로서 유용한 화합물의 제조방법
FR2947266B1 (fr) * 2009-06-26 2011-06-17 Servier Lab Nouveaux derives d'acide 2-mercaptocyclopentanecarboxylique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US8410127B2 (en) 2009-10-01 2013-04-02 Metabolex, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
KR20130006620A (ko) * 2010-03-18 2013-01-17 다이이찌 산쿄 가부시키가이샤 시클로프로판카르복실산 유도체
DK2548871T3 (da) 2010-03-18 2017-11-06 Daiichi Sankyo Co Ltd Cycloalkylsubstitueret imidazolderivat
MX2013004193A (es) * 2010-11-11 2013-06-05 Sanofi Sa Procedimiento para la preparacion de derivados de acido 3-(6-amino-piridin-3-il)-2-acrilico.
EP2782576B1 (en) 2011-11-25 2016-05-18 Sanofi Sodium salt of (r)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1h-imidazol-4-yl)-propionic acid
EP2782574B1 (de) 2011-11-25 2016-03-30 Sanofi Salz von (r)-3-(6-amino-pyridin-3-yl)-2-(1-cyclohexyl-1h-imidazol-4-yl)- propionsäureethylester
EP2782575B1 (en) 2011-11-25 2016-04-20 Sanofi Crystalline salts of r)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1h-imidazol-4-yl)-propionic acid
EP3184095A1 (en) 2013-05-23 2017-06-28 IP Gesellschaft für Management mbH Administration units comprising polymorph 1 of 2-(2-methylamino-pyrimidin-4-yl]-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide
CA2914533A1 (en) 2013-06-10 2014-12-18 Sanofi Macrocyclic urea derivatives as inhibitors of tafia, their preparation and their use as pharmaceuticals
EP3437641A4 (en) 2016-03-29 2019-11-20 Daiichi Sankyo Company, Limited THERAPEUTIC AGENT AGAINST INFLAMMATORY DARMER DISEASE
AU2017305392A1 (en) 2016-08-03 2019-02-21 Cymabay Therapeutics, Inc. Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0104657A3 (en) * 1998-12-24 2002-07-29 Astellas Pharma Inc Chuo Ku Imidazole compounds and pharmaceutical compositions containing them
WO2003013526A1 (en) * 2001-08-08 2003-02-20 Merck & Co. Inc. Anticoagulant compounds
WO2003061653A1 (en) 2002-01-22 2003-07-31 Pfizer Limited 3-(imidazolyl)-2-aminopropanoic acids for use as tafi-a inhibitors for the treatment of thrombotic diseases

Also Published As

Publication number Publication date
KR101162047B1 (ko) 2012-07-04
JP2007533672A (ja) 2007-11-22
TW200602325A (en) 2006-01-16
HRP20080099T3 (en) 2008-03-31
DK1740569T3 (da) 2008-06-02
TNSN06341A1 (en) 2008-02-22
MA28543B1 (fr) 2007-04-03
CN1950357A (zh) 2007-04-18
BRPI0510159A (pt) 2007-10-02
PL1740569T3 (pl) 2008-07-31
NI200600217A (es) 2008-06-17
RU2006141246A (ru) 2008-06-10
NO20065320L (no) 2007-01-12
CY1108087T1 (el) 2014-02-12
ATE523505T1 (de) 2011-09-15
IL178672A (en) 2011-08-31
IL178672A0 (en) 2007-02-11
DE502005002927D1 (de) 2008-04-03
SI1740569T1 (sl) 2008-06-30
NZ550757A (en) 2010-06-25
AR053302A1 (es) 2007-05-02
AU2005238144B2 (en) 2010-08-26
RS50553B (sr) 2010-05-07
RU2375356C2 (ru) 2009-12-10
UA87306C2 (en) 2009-07-10
ES2299026T3 (es) 2008-05-16
CA2563401C (en) 2012-08-07
PT1740569E (pt) 2008-03-31
CR8650A (es) 2007-12-04
HK1101823A1 (zh) 2007-10-26
CA2563401A1 (en) 2005-11-10
ECSP066941A (es) 2006-12-20
EP1864979A1 (de) 2007-12-12
EP1740569B1 (de) 2008-02-20
ZA200607668B (en) 2008-03-26
CN100572376C (zh) 2009-12-23
TWI359016B (en) 2012-03-01
ATE386737T1 (de) 2008-03-15
DE102004020186A1 (de) 2005-11-17
KR20070007346A (ko) 2007-01-15
UY28868A1 (es) 2005-11-30
WO2005105781A1 (de) 2005-11-10
AU2005238144A1 (en) 2005-11-10
JP4939401B2 (ja) 2012-05-23
EP1864979B1 (de) 2011-09-07
PE20060172A1 (es) 2006-03-31
EP1740569A1 (de) 2007-01-10

Similar Documents

Publication Publication Date Title
MY140903A (en) Imidazole derivatives used as tafia inhibitors
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
PH12012501768A1 (en) Piperidin-4-yl azetidine derivatives as jak1 inhibitors
GB2466912A (en) Compositions and methods for treating lysosomal disorders
WO2009126863A3 (en) Pyridyl inhibitors of hedgehog signalling
PT1984357E (pt) Compostos de 2,4-pirimidinadiamina para tratamento ou prevenção de doenças autoimunes
MX2009006195A (es) Compuestos basados en 4-fenil-6-(2,2,2-trifluoro-1-feniletoxi)piri midina y metodos de su uso.
WO2006106326A8 (en) Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors
TNSN08373A1 (en) Azolopyrimidines as inhibitors of cannabinoid 1 activity
WO2008022286A3 (en) Small molecule inhibitors of kynurenine-3-monooxygenase
NO20083923L (no) Pyrazolkinoloner er potente parp-inhibitorer
MX2009010960A (es) Compuestos heterociclicos y sus metodos de uso.
WO2010033701A3 (en) Inhibitors of sphingosine kinase 1
UA83875C2 (ru) Производные хинолина для применения в качестве микобактериальных ингибиторов
IL195217A0 (en) Protein kinase inhibitors and uses thereof
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
UA104002C2 (ru) МАКРОЦИКЛИЧЕСКИЕ ПРОИЗВОДНЫЕ МОЧЕВИНЫ И СУЛЬФАМИДА КАК ИНГИБИТОРЫ TAFIa
TW200736229A (en) Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
NO20082096L (no) Azaindol-2-karboksamidderivativer
ATE542800T1 (de) Kinasehemmer und ihre anwendungsverfahren
WO2010021934A3 (en) Azaindole inhibitors of iap
MX2010007543A (es) Inhibidores de iap.
TW200700064A (en) Novel compounds
MX2009005516A (es) Derivados de urea y de sulfamida en calidad de inhibidores de tafia.
WO2006028963A3 (en) Substituted heterocyclic compounds and uses thereof